Cabbacis Reports Full Year 2025 Financial Results and Provides Corporate Update
Cabbacis (OTCQB: CABI), a federally-licensed tobacco-product manufacturer focused on its patented risk-reduction products being developed under the iBLEND™ brand name, today announced that it has filed its Annual Report on Form 1-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”).
Cabbacis to Present at the Noble Emerging Growth Equity Conference on February 4, 2026
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on risk-reduction products being developed under the iBlend™ brand name, today announced that management will attend the upcoming Noble Emerging Growth Virtual Equity Conference on February 4-5, 2026.
Cabbacis Issues Shareholder Letter and Provides Corporate Update
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on risk-reduction products being developed under the iBlend™ brand name, today issued a letter to shareholders from Joseph Pandolfino, Chairman & Chief Executive Officer of Cabbacis.
Cabbacis Granted U.S. Patent for Vaporizer Pods Containing Tobacco and Hemp
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on its patented harm-reduction products being developed under the iBlend™ brand name, today announced that the United States Patent and Trademark Office has issued a patent to Cabbacis for vaporizer pods for oral electronic vaporizers.
Cabbacis to Host Live Webinar to Discuss $7.5 Million Offering and its Better Smoking and Vaping Alternatives
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on its patented, iBlend™ harm-reduction products, today announced that as part of its $7.5 million Regulation A offering, the Company will host an Investor Webinar on Thursday, January 22, 2026 at 11:30 AM ET.
Cabbacis to Present at the Noble Emerging Growth Conference on October 8, 2025
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, today announced that management will attend the upcoming Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference, on October 8th and 9th 2025.
Cabbacis Provides First Half 2025 Corporate Update
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, today provided a corporate update in conjunction with the filing of its Semiannual Report on Form 1-SA for the first half ended June 30, 2025.
Cabbacis to Attend the Q3 Virtual Investor Summit on September 16 – 17, 2025
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, today announced that management will attend the upcoming Q3 Virtual Investor Summit on September 16th and 17th 2025.
Cabbacis Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name (the “Company”), today announced the engagement of international investor relations specialists MZ Group (“MZ”) to lead a strategic investor relations and financial communications program across all key markets.
Cabbacis Granted U.S. Patent for Vaporizer Pods
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, today announced that the United States Patent and Trademark Office has issued a patent to Cabbacis for vaporizer pods for oral electronic vaporizers.
Cabbacis Obtains DTC Eligibility
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on tobacco harm-reduction products, is pleased to announce the Company has received approval from the Depository Trust Company (DTC) yesterday to make its common shares eligible to be electronically cleared and settled (DTC Eligibility).
iBlend.com Domain Acquired by Cabbacis
Cabbacis (the "Company"), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that it has purchased the www.iBlend.com domain to feature the iBlend™ brand.
Cabbacis Announces IPO Via Regulation A
Cabbacis Inc (“Cabbacis” or the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that the Company has launched a $5 million, Regulation A (Tier 2), initial public offering.
